Compounded semaglutide injection recalled after testing subpotent in three lots
Semaglutide 2.5 mg/mL injection, 4 mL, from Boothwyn Pharmacy is recalled nationwide as a subpotent drug. 648 vials are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported; a subpotent injectable medicine may not deliver the intended dose and no injuries are reported.
Plain-English summary
Semaglutide, 2.5 mg/mL injection, 4 mL, from Boothwyn Pharmacy is being recalled. The affected product carries codes 03202025@2, 03202025@3 and 03202025@4, with a beyond-use date of 07/18/2025. The recall covers 648 vials distributed nationwide.
The recall was issued because the product is subpotent. The FDA classified the action as Class II.
Patients should check the code on their vial against the recall and speak to their prescriber or pharmacy about a replacement supply before stopping a prescribed treatment.
The recalled product
- Product
- Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy
- Manufacturer
- Boothwyn Pharmacy LLC
- Category
- Drug — Compounded Injectable
- Hazard
- subpotency
- compounded-drug
- injectable
- class-ii
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 03202025@2
- 03202025@3 and 03202025@4 BUD 07/18/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- HighXylocaine Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29
- ModerateFDA Recalls Xylocaine Injections Due to Hair Contamination
FDA (Drugs) · 2026-07-29
- HighNaropin Injection Recall Over Particulate Matter Contamination
FDA (Drugs) · 2026-07-29
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency Nationwide
FDA (Drugs) · 2026-07-29